Targeted treatment approach shows potential to reshape how antidepressants are prescribed
Targeted treatment approach shows potential to reshape how antidepressants are prescribed
Two key developments in US oncology signal faster progress: a new standard therapy for aggressive colorectal cancer and …
Prime Minister Starmer unveils ambitious reforms to speed up trial timelines and centralize NHS data, aiming to restore …
An investigational RNA-based therapy shows significant reduction in disease-causing protein levels—potentially a meaningful step forward in treating Huntington’s …
Vera Therapeutics completed full enrolment in its pivotal trial of atacicept in IgA nephropathy and Minovia Therapeutics received …
In a shareholder letter released on 1 April 2025, MAIA Biotechnology revealed plans to advance telomere‐targeted therapies in …
Experimental gene-silencing drug lepodisiran delivers long-lasting reduction of cardiovascular risk factor, while Spinogenix launches trial for novel synaptic …
Viking Therapeutics and Bluejay Therapeutics highlight progress in obesity management and neurological disease treatment with key clinical milestones.
Merck’s global license deal for HRS-5346 and Tiziana’s intranasal foralumab Phase 2 trial signify strides in cardiovascular and …
Abbott receives FDA approval to begin Phase 3 trial of its Intravascular Lithotripsy system aimed at improving outcomes …
Already a subscriber? Log in